Atrium Arises From Novartis’s Avidity Buyout

 
• By Joseph Haas
  
Atrium will focus on early-stage cardiomyopathy candidates delivered directly to the heart (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business